首页 | 本学科首页   官方微博 | 高级检索  
     


Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles
Authors:Maria Sokol  Ivan Gulyaev  Mariia Mollaeva  Sergey Kuznetsov  Vladimir Zenin  Maksim Klimenko  Nikita Yabbarov  Margarita Chirkina  Elena Nikolskaya
Affiliation:1. Laboratory of quantitative oncology, N. M. Emanuel Institute of Biochemical Physics RAS, Moscow, Russia;2. Laboratory of quantitative oncology, N. M. Emanuel Institute of Biochemical Physics RAS, Moscow, Russia

Department of Chemistry and Technology of Biomedical Preparations, Mendeleev University of Chemical Technology of Russia, Moscow, Russia;3. Department of Nanobiomaterials and Structures, National Research Center “Kurchatov Institute”, Moscow, Russia;4. Laboratory of molecular biotechnology, Federal State Institution, Federal Research Centre, Fundamentals of Biotechnology, Russian Academy of Sciences, Moscow, Russia

Abstract:While histone deacetylase inhibitors, such as vorinostat, demonstrate a significant effect against hematological cancers, their application for solid tumor treatment is limited. However, there is strong evidence that combinatorial administration of vorinostat and genotoxic agents (e.g., doxorubicin) enhances the antitumoral action of both drugs against tumors. We developed a high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles designed to provide the parenteral administration of both drugs and increase their safety profile. We performed separation on Nucleodur C-18 Gravity column with a mixture of 10 mM potassium dihydrogen phosphate buffer pH 3.9:ACN (90:10 v/v) as mobile phase at 240 nm. The method was linear within the concentration range of 4.2–52.0 μg/ml for both drugs with limits of detection and quantification of 3.5 and 10.7 μg/ml for doxorubicin and 2.5 and 7.7 μg/ml for vorinostat, respectively. The method was precise and accurate over the concentration range of analysis. Drug loading was 5.4% for doxorubicin and 0.8% for vorinostat. Degradation of doxorubicin after irradiation was less than 5%, while the amount of vorinostat decreased at 88% under the same conditions. Thus, the validated method could be adopted for routine simultaneous analysis of doxorubicin and vorinostat in polymeric nanoparticles.
Keywords:Box-Behnken design  doxorubicin  nanoparticles  validation  vorinostat
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号